Drug Profile
Research programme: insulin and leptin sensitisers - Signum Pharmaceuticals
Latest Information Update: 02 Aug 2007
Price :
$50
*
At a glance
- Originator Signum Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 02 Aug 2007 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 02 Aug 2007 No development reported - Preclinical for Obesity in USA (unspecified route)
- 22 May 2006 Preclinical trials in Diabetes mellitus in USA (unspecified route)